Invetx Inc., a pioneer in protein-based therapeutics for animal health, has agreed to be acquired by Dechra Pharmaceuticals Limited for up to $520 million. This acquisition will complement Dechra’s broad portfolio of specialty therapeutics for companion animals and accelerate its differentiated position in the veterinary health industry. Invetx’s pipeline of monoclonal antibody therapeutics and species-specific, half-life extension platform will further enhance Dechra’s expertise in core therapeutic areas.